Sareum Holdings PLC
22 October 2007
For immediate release 22 October 2007
SAREUM HOLDINGS PLC
("Sareum" or "the Company")
Fundraising
Sareum Holdings plc (AIM: SAR), the specialist structure-based drug discovery
business, is pleased to announce that it has agreed to place 138,888,889
Ordinary Shares of 0.025p nominal value at a price of 0.9p per share to raise
£1.25 million before expenses. 25,944,889 of these shares are being placed
subject to approval at the Company's AGM on 15 November 2007.
Mr and Mrs Leonard Licht have agreed to subscribe to 33,333,333 new Ordinary
Shares and together will hold 13.43% of the Company's enlarged issued share
capital1. The Directors of the Company have agreed to subscribe to 2,000,000 new
Ordinary Shares. The remainder is being placed with clients of the Company's
broker, Ellis Stockbrokers Limited.
Mr Leonard Licht is a Partner of Hg Capital and previously has been a former
founding director and Vice Chairman of Mercury Asset Management and the Deputy
Chairman of Jupiter Tyndall Group.
The funds raised from this share issue will used to advance the Company's
in-house development pipeline of cancer drug candidates and to provide
additional working capital.
The Directors share purchases are:
Name Number of shares Number of shares held Percentage of issued
purchased following share purchase share capital1
Dr Paul Harper 1,111,111 2,444,444 0.41%
Dr Tim Mitchell 111,111 42,780,471 7.15%
Mr Giorgio Reggiani 555,556 555,556 0.09%
Dr John Reader 111,111 43,447,111 7.26%
Dr David Williams 66,667 42,735,987 7.14%
Application has been made for the admission of 112,944,000 shares to trading on
AIM with admission expected to take place on 26 October 2007. Application will
be made for the admission of 25,944,889 shares to trading on AIM with admission
expected to take place on 21 November 2007.
1 Percentage of share capital assuming AGM approval for the issue of 25,944,889
new Ordinary Shares.
Commenting on the announcement, Sareum's Chief Executive Officer, Dr Tim
Mitchell said: "This placing will provide valuable funds to advance our in-house
cancer programs towards a stage where they become attractive licencing
opportunities. We are also very pleased that Mr and Mrs Licht have chosen to
increase their shareholding in Sareum."
For further information:
Sareum Holdings plc 01223 497700
Tim Mitchell, Chief Executive Officer
Buchanan Communications 020 7466 5000
Tim Anderson, Mary-Jane Johnson
Grant Thornton Corporate Finance 020 7383 5100
Philip Secrett, Colin Aaronson
Notes for editors:
About Sareum Holdings plc
Sareum Holdings plc is a structure-based drug discovery business headquartered
in Cambridge, UK. The Company was formed in August 2003 to discover new drugs
for the treatment of cancer. Sareum's unique approach aims to halve the time it
takes to discover new drug candidates.
A structure-based approach to drug discovery relies on knowledge of the
three-dimensional structure of the proteins that cause disease. Once the
structure is known, potential drugs are designed to 'lock-in' to the protein
with the aim of reversing or arresting a disease's progression. Knowledge of
the structure of the potential drugs and how they 'lock-in' to their target
protein assists greatly in the development of high-quality drug candidates.
Determining structure is a complex task and requires leading-edge equipment and
experienced staff. Sareum's approach to structure determination utilises its
proprietary protein expression platform in order to produce multiple recombinant
proteins that accelerate structure determination using x-ray crystallography.
Once the structure is determined, the Company's innovative fragment screening
platform is used to identify novel chemical templates designed to interact with
the target protein. Sareum then uses its high-throughput medicinal chemistry
platform to rapidly optimise these molecules and develop the most promising into
potential drug candidates.
Sareum aims to successfully deliver drug candidates for licensing to larger
pharmaceutical companies at the pre-clinical or early clinical trials stage.
This is funded by provision of its specialist drug discovery capabilities to
partners in the pharmaceutical and biotechnology industries.
Sareum joined the AIM market of the London Stock Exchange in October 2004 and
trades under the symbol SAR. For further information, please visit
www.sareum.co.uk
This information is provided by RNS
The company news service from the London Stock Exchange
AI Summary Disclaimer BETA
The content you are viewing has been generated or assisted by artificial
intelligence (AI). While efforts are made to ensure accuracy and clarity, AI-generated text may
contain inaccuracies, outdated information, or subjective interpretations. This content is intended
for general informational purposes only and should not be considered professional advice or factual
confirmation.
We encourage you to independently verify any information provided,
especially if it will be relied upon for making decisions or taking action. Any reliance you place
on this material is strictly at your own risk. The AI system that produced this content cannot
assess the specifics of individual circumstances, and results may vary based on context and
individual needs.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.
Create an Account
Create your FREE account to receive personalised announcements, watchlists, market updates, investment insights and new features.
Personalise your experience
Tell us a little about yourself to receive personalised content, announcements and relevant investment opportunities.